Amgen

Amgen, a US-based Pharmaceutical Preparation Manufacturing company, reported its total greenhouse gas emissions for 2024 as approximately 1,866,353,000 kg CO2e. This includes Scope 1 emissions of approximately 147,353,000 kg CO2e, Scope 2 emissions of approximately 14,000,000 kg CO2e (market-based), and Scope 3 emissions of approximately 1,705,000,000 kg CO2e.

Looking back, Amgen's Scope 1 emissions were approximately 153,000,000 kg CO2e in 2023, 130,000,000 kg CO2e in 2022, 133,000,000 kg CO2e in 2021, 139,000,000 kg CO2e in 2020, and 136,000,000 kg CO2e in 2019. Scope 2 emissions were approximately 12,000,000 kg CO2e in 2023, 35,000,000 kg CO2e in 2022, 58,000,000 kg CO2e in 2021, 136,000,000 kg CO2e in 2020, and 160,000,000 kg CO2e in 2019.

Amgen has set several climate commitments. The company aims to achieve carbon neutrality for Amgen-owned and operated facilities and operations (Scopes 1 and 2) by 2027. They are also striving for 100% renewable electricity use at all operations where feasible by 2027, which is expected to result in approximately a 50% reduction in carbon emissions from operations.

As of 2023, Amgen had achieved 54% of its targeted reductions for Scope 1 and 2 carbon emissions, using a 2019 baseline. The company has also committed to Science Based Targets initiative (SBTi) approved goals. These include reducing absolute Scope 1 and 2 GHG emissions by 55% by 2027 from a 2019 base year. Furthermore, Amgen commits to increasing annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, and to continue annually sourcing 100% renewable electricity through 2030. Amgen has also committed that 73% of its suppliers by spend, covering upstream purchased goods and services and capital goods, will have science-based targets by 2027.